Voyager Therapeutics positions itself as a key player in neurological therapeutics with ambitious 2025 plans. The biotech company is advancing two tau-targeting assets, including a C-terminal antibody expected to deliver tau PET imaging data by year-end and a gene therapy tau knockdown program similar to competitor BIIB080. A major milestone involves deploying newly discovered blood-brain barrier penetrant capsids in clinical settings for the first time, with applications spanning tau knockdown and a Friedreich's ataxia program developed with partner Neurocrine. These developments represent critical proof-of-concept opportunities for Voyager's proprietary capsid technology in the competitive neuro space.
Post from MarketNews_en
Log in to interact with content.